X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Study finds middlemen excluded nearly 850 medicines from formularies this year

By Katie Koziara  |    September 17, 2020
A new study from Xcenda finds that from 2014 to 2020, the number of medicines excluded by at least one of the three largest pharmacy benefit managers (PBMs) from their standard formularies...   Read More

Recent administration actions undermine patient assistance programs

By Nicole Longo  |    September 16, 2020
While all eyes and ears are focused on COVID-19 and beating this pandemic, the administration has pursued harmful policy changes that we can’t let slip under the radar. In two back-to-back...   Read More

Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually

By Gabby Migliara  |    August 19, 2020
A recent analysis by IQVIA shows that chronically ill patients who used manufacturer cost-sharing assistance in 2019 saved hundreds to thousands of dollars on their out-of-pocket costs. IQVIA...   Read More

Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas

By Gabby Migliara  |    August 12, 2020
According to a recent IQVIA analysis, commercial health plans have increased patients’ average out-of-pocket costs for brand medicines by over 50% in some therapeutic areas since 2015. Notably, of...   Read More

Commercial health plans’ transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs for brand medicines

By Gabby Migliara  |    August 6, 2020
A decade ago, most patients paid only copays for brand medicines. But in recent years, use of deductibles and coinsurance in commercial health plans has skyrocketed. According to a recent IQVIA...   Read More

Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report

By Katie Koziara  |    August 5, 2020
Today, IQVIA released a new report, Medicine Spending and Affordability in the U.S., providing context on medicine price and spending trends and patient out-of-pocket costs. The report highlights...   Read More

New data show commercially insured patients face increasingly high cost sharing for brand medicines

By Gabby Migliara  |    July 30, 2020
New data show deductibles and coinsurance result in high out-of-pocket spending for commercially insured patients taking brand medicines. IQVIA analyzed trends in cost sharing across seven therapy...   Read More

Payers subject 80% of new RA and MS patients to utilization management restrictions

By Gabby Migliara  |    July 22, 2020
A new analysis from IQVIA shows that in 2018, 80% of commercially insured patients attempting to fill a new prescription for a rheumatoid arthritis (RA) or multiple sclerosis (MS) medicine...   Read More

New rule makes it harder for patients to lower their out-of-pocket costs

By Holly Campbell  |    May 20, 2020
In the midst of increased financial insecurity for Americans due to the COVID-19 pandemic, it is shocking the Administration finalized a policy change in the 2021 Notice of Benefit and Payment...   Read More

ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements

By Katie Koziara  |    April 20, 2020
Value-based programs between biopharmaceutical companies and pharmacy benefit manager Express Scripts saved $4.3 billion on medicines last year. Patients in these plans with innovative contracting...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates